Partner With Us NRI

Aurobindo Pharma Ltd share Price Today

Company details

6M Return 56.96%
1Y Return 121.19%
Mkt Cap.(Cr) 60,571.44
Volume 1,227,116
Div Yield 0.73%
OI Chg %
Volume 1,227,116

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Revenues beat but margins still below par..
About The Stock

    Aurobindo is a significant global generics player with 28 manufacturing facilities, including eight key formulations facilities in India and abroad along with three R&D centres. The current employee strength is more than 8000, which includes more than 750 scientists.

    • FY22, API: formulations ratio was at 15:85. US formulations constitute 47% of revenues followed by Europe (28   %), APIs (15%), RoW (6%) & ARV (4%)
    • Aurobindo is setting up a plant for production of Penicillin-G with capacity of 15,000 MT for ₹ 1850 crore, under the PLI scheme

    Revenues were muted & below I-direct estimates, margins in line.

    • Revenues were down 3% YoY to ₹ 5809 crore
    • EBITDA was at ₹ 974 crore, down 24% YoY with margins at 16.8%

    Adjusted PAT was at ₹ 734.5 crore, down 8% YoY [note: profit is adjusted for one-off of ₹ 162.7 crore in Q4FY22]

Click here for full recommendation

Research view on more stocks

Pharmaceutical company Aurobindo Pharma announced Q2FY24 results:

  • Revenue from operations increased by 25.8% YoY to Rs 7,219 crore with growth seen across key segments
  • US formulations (excluding Puerto Rico) revenue increased by 35.7% YoY to Rs 3,385 crore (USD 409 million)
  • Europe formulation revenue increased by 16.7% YoY to Rs 1,769 crore (EUR 197 million)
  • Growth markets revenue increased by 24.7% YoY to Rs 564 crore (USD 68 million)
  • ARV revenue increased by 52.1% YoY to Rs 250 crore (USD 30 million)
  • API revenue grew by 20.3% YoY to Rs 1,166 crore
  • EBITDA before Forex and Other income stood at Rs 1,403 crore; EBITDA margin of 19.4 %
  • Research & Development (R&D) spend stood at Rs 300 crore, 4.2% of revenues (vs. Q1 FY24: 5.7%)
  • Received final approval for 15 ANDAs including 3 injectable products from the USFDA
  • Net Profit after Share of Profit/Loss of JV and minority interest at Rs 752 crore, vs. Rs 409 crore in Q2FY23
  • Basic & Diluted EPS grew by 83.6% YoY to Rs 12.83 per share
  • Board has approved interim dividend at 300% i.e. Rs 3 per equity share of Re 1 for the year FY24

Commenting on the company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said, “This is yet another quarter with highest ever sales, driven by robust performance across the markets, and continued margin expansion, aided by operational leverage and efficiencies. With our strong product pipeline, focus on compliance and key projects in advanced stages, we will continue our growth journey, while generating value for our stakeholders.”


Result PDF

View Other Company Results


Investment recommendation
Revenues beat but margins still below par..
Call Date
21 Feb 2023
Entry Price 464.00
Target Price 525.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Aurobindo Pharma Ltd Stocks COMPARISION


Equity Capital: 26,839.85 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 15,779.50 22,156.90
LAST 3M 54,802.13 -2,099.03
LAST 6M 93,089.45 78,838.27
LAST 12M 161,092.98 118,023.38
Aurobindo Pharma Limited - Loss of Share Certificates

Dec 01, 2023 l NSE Announcement

Eugia Pharma Specialities receives USFDA approval for Budesonide Inhalation Suspension

Nov 30, 2023 l BSE Announcement

Aurobindo Pharma Limited - Press Release

Nov 30, 2023 l NSE Announcement

Date Action Type Ratio
Nov 20, 2023 Dividend 300
Feb 17, 2023 Dividend 300
Jun 06, 2022 Dividend 450

Aurobindo Pharma Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Aurobindo Pharma is a distinguished name in the pharmaceutical industry. It was incorporated in 1986, and its headquarters is located in Hyderabad. As of 31 December 2021, it reported a net income of Rs 604.73 crore. The prominent faces in Aurobindo Pharma management are—Mr K Raghunathan, Mr K Nityananda Reddy, Dr M. Sivakumaran, Mr P. V Ram Prasad Reddy, and a few more. Aurobindo Pharma’s valuation on the stock exchange is Rs 30,636 crore. 

    The company is listed on both the stock exchanges of India, that is NSE and BSE. It is traded under the symbol AURO PHARMA. 

    The company is primarily into the development, manufacturing, and supply of active pharmaceutical ingredients, generic pharmaceuticals, and branded speciality pharmaceuticals. Some key offerings in its product portfolio cater to/include antibiotics, central nervous system, anti-diabetics, gastroenterological, anti-retroviral, and cardiovascular. The company currently supplies its products to more than 150 countries. Its subsidiary company list includes Aurolife Pharma LLC, APL Healthcare, Auro Peptides Ltd, Auronext Pharma Pvt. Ltd. and a few more. 

    Now, if you dive into the company’s financials, you will find the following.

    Aurobindo Pharma’s price-to-equity ratio or PE ratio (6.13) and price-to-book ratio or PB ratio (1.49) are better than the industry’s average. The same is the case with revenue and net income. Over the past five years, Aurobindo Pharma’s revenue and income have grown at an annual rate of 15.2% and 21.38%, respectively. For the same period, the industry’s average income and revenue growth rates were 6.94% and 8.25%, respectively. Aurobindo Pharma’s total liabilities declined by Rs 467.41 crore compared to the financial year 2020. Even after reducing the liabilities, the company cash flow statement shows a free cash flow of Rs 1455.11 crore in FY20-21. 

    On 20 May 2022, the Aurobindo Pharma share price on NSE closed at Rs 557.95. It was 6.71% higher than the previous day’s closing price. The last 52 weeks’ movement of Aurobindo Pharma Ltd.’s share price on the stock market saw a high of Rs 1,043.10 and a low of Rs 520.85. Investing in Aurobindo Pharma shares carries a low amount of risk since its price volatility is 1.95x that of the Nifty.  The key names in its peers’ list are Cipla Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Tel : 91-40-23736370
Email : info:aurobindo.com/investorgrievances:aurobindo.co
Website : http://www.aurobindo.com

KFin Techologies Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524804
Book Closure Date (Month) :
BSE Group : A
ISIN : INE406A01037

FAQ’s on Aurobindo Pharma Ltd Shares

You can buy Aurobindo Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aurobindo Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Dec 01, 2023 03:59 PM the closing price of Aurobindo Pharma Ltd was ₹ 1,033.75.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Dec 01, 2023 03:59 PM, the market cap of Aurobindo Pharma Ltd stood at ₹ 60,571.44.

The latest PE ratio of Aurobindo Pharma Ltd as of Dec 01, 2023 03:59 PM is 25.6

The latest PB ratio of Aurobindo Pharma Ltd as of Dec 01, 2023 03:59 PM is 0.47

The 52-week high of Aurobindo Pharma Ltd is ₹ 1,059.65 while the 52-week low is ₹ 397.20

According to analyst recommendations, Aurobindo Pharma Ltd has a “Buy” rating for the long term.

Download Our App

market app
market app